A nurse is caring for a client at risk for atelectasis. Which independent nursing measure should the nurse prioritize to prevent atelectasis development?

A. The medication will open the airways: Albuterol is a bronchodilator that works by relaxing the muscles around the airways, leading to dilation and increased airflow. This action helps to relieve symptoms of asthma or chronic obstructive pulmonary disease (COPD), making it easier for the client to breathe. The nurse should emphasize that opening the airways is a primary function of albuterol, providing immediate relief during breathing difficulties.
B. The medication will stimulate the flow of mucus: Albuterol does not primarily stimulate mucus production; rather, its main role is to relax bronchial smooth muscle and open the airways. While effective airway management may lead to improved mucus clearance due to enhanced airflow, albuterol itself does not directly promote mucus secretion. Thus, this statement does not accurately describe the action of the medication.
C. The medication will decrease coughing episodes: By opening the airways and improving airflow, albuterol can help reduce coughing episodes associated with bronchospasm or airway constriction. When the airways are less constricted, the client is less likely to experience the irritative cough often seen in respiratory conditions like asthma. This is an important point for the nurse to convey to help the client understand the medication's benefits.
D. The medication will prevent wheezing: Albuterol can help prevent or relieve wheezing by relaxing the bronchial muscles and facilitating better airflow. Wheezing often occurs when the airways are narrowed or constricted, and by using albuterol, the client can experience fewer wheezing episodes during respiratory distress. The nurse should explain this aspect to reinforce the medication's role in managing asthma or COPD symptoms.
E. The medication will reduce inflammation: Albuterol is not an anti-inflammatory medication; it primarily functions as a bronchodilator. While it can improve breathing by relaxing airway muscles, it does not directly target inflammation in the airways. Inhaled corticosteroids or other anti-inflammatory medications are typically used to address inflammation. Therefore, this response does not accurately reflect the action of albuterol.

A. Incentive spirometry: This is the most effective independent nursing measure to prevent atelectasis. Incentive spirometry encourages deep breathing and lung expansion, which helps to keep the alveoli open and reduces the risk of collapse. It is particularly beneficial for clients at risk for atelectasis, such as those who have had surgery, are immobile, or have respiratory issues. Regular use of the incentive spirometer promotes optimal lung function and helps prevent the development of atelectasis.
B. Increase oral fluid intake: While maintaining adequate hydration is important for overall health and can help thin secretions, it is not as directly effective in preventing atelectasis as incentive spirometry. Increased fluid intake alone does not promote deep breathing or lung expansion, which are critical in preventing airway collapse.
C. Ambulation: Although ambulation is an important intervention for promoting overall mobility and respiratory function, it may not be as practical for all clients, especially those who are unable to move independently. While getting the client up and moving can help prevent atelectasis, the most immediate and effective measure remains the use of incentive spirometry, which can be performed regardless of the client’s mobility status.
D. Oxygen therapy: While oxygen therapy can help improve oxygenation in clients with respiratory issues, it does not directly prevent atelectasis. Providing supplemental oxygen does not address the need for lung expansion and deep breathing, which are essential in maintaining alveolar patency. Therefore, oxygen therapy should not be prioritized as the primary independent measure to prevent atelectasis.